Results 1 to 10 of about 583,526 (226)
Programmable polymorphism of a virus-like particle
Communications Materials, 2022 Virus-like particles are promising for drug delivery systems and vaccine development, but controlling their size and morphology is challenging. Here, amino acid sequences are inserted into MS2 bacteriophage virus-like particles, with their size and shape
Artur P. Biela +4 more
doaj +2 more sources
Virus-like Particle Vaccines and Platforms for Vaccine Development
Viruses, 2023 Virus-like particles (VLPs) have gained a lot of interest within the past two decades. The use of VLP-based vaccines to protect against three infectious agents—hepatitis B virus, human papillomavirus, and hepatitis E virus—has been approved; they are ...
Milad Kheirvari +2 more
doaj +2 more sources
Zika virus-like particle (VLP) based vaccine. [PDF]
PLoS Neglected Tropical Diseases, 2017 The newly emerged mosquito-borne Zika virus poses a major public challenge due to its ability to cause significant birth defects and neurological disorders.
Hélène Boigard +5 more
doaj +2 more sources
Preclinical Development of a Novel Zika Virus-like Particle Vaccine in Combination with Tetravalent Dengue Virus-like Particle Vaccines [PDF]
VaccinesDeclared as a Public Health Emergency in 2016 by the World Health Organization (WHO), the Zika virus (ZIKV) continues to cause outbreaks that are linked to increased neurological complications.
Dominik A. Rothen +12 more
doaj +2 more sources
Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1
Frontiers in Immunology, 2018 It is acknowledged that vaccines remain the best hope for eliminating the HIV-1 epidemic. However, the failure to produce effective vaccine immunogens and the inability of conventional delivery strategies to elicit the desired immune responses remains a ...
Yong Gao +2 more
doaj +2 more sources
Virus-like particle vaccines: immunology and formulation for clinical translation
Expert Review of Vaccines, 2018 Introduction: Virus-like particle (VLP) vaccines face significant challenges in their translation from laboratory models, to routine clinical administration. While some VLP vaccines thrive and are readily adopted into the vaccination schedule, others are
Braeden Donaldson +4 more
doaj +2 more sources
Optimization and validation of a virus‐like particle pseudotyped virus neutralization assay for SARS‐CoV‐2 [PDF]
MedCommSpike‐protein‐based pseudotyped viruses were used to evaluate vaccines during the COVID‐19 pandemic. However, they cannot be used to evaluate the envelope (E), membrane (M), and nucleocapsid (N) proteins. The first generation of virus‐like particle (VLP)
Shuo Liu +12 more
doaj +2 more sources
Advances in virus-like particle-based SARS-CoV-2 vaccines [PDF]
Frontiers in Cellular and Infection MicrobiologyThe Coronavirus Disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has incurred devastating human and economic losses. Vaccination remains the most effective approach for controlling the COVID-19
Xiaoting Hao, Feifei Yuan, Xuan Yao
doaj +2 more sources
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
International Journal of Molecular Sciences, 2023 Cancer vaccines are increasingly being studied as a possible strategy to prevent and treat cancers. While several prophylactic vaccines for virus-caused cancers are approved and efficiently used worldwide, the development of therapeutic cancer vaccines ...
F. Ruzzi +8 more
semanticscholar +1 more source
Virus-like particle vaccinology, from bench to bedside
Cellular & Molecular Immunology, 2022 Virus-like particles (VLPs) have become key tools in biology, medicine and even engineering. After their initial use to resolve viral structures at the atomic level, VLPs were rapidly harnessed to develop antiviral vaccines followed by their use as ...
Mona O. Mohsen, Martin F. Bachmann
semanticscholar +1 more source